Page 137 - 《中国药房》2023年24期

terol Nutr，2019，69（1）：68-74. bowel disease[J]. Gastroenterology，2017，153 （3） ：
[ 5 ] GONCZI L，VEGH Z，GOLOVICS P A，et al. Prediction 827-834.
of short- and medium-term efficacy of biosimilar infli- [16] MITREV N，VANDE CASTEELE N，SEOW C H，et al.
ximab therapy. Do trough levels and antidrug antibody le- Review article：consensus statements on therapeutic drug
vels or clinical and biochemical markers play the more im‐ monitoring of anti-tumour necrosis factor therapy in in‐
portant role?[J]. J Crohns Colitis，2017，11（6）：697-705. flammatory bowel diseases[J]. Aliment Pharmacol Ther，
[ 6 ] DAVIDOV Y，UNGAR B，BAR-YOSEPH H，et al. Asso‐ 2017，46（11/12）：1037-1053.
ciation of induction infliximab levels with clinical re‐ [17] 中华医学会消化病学分会炎症性肠病学组. 中国炎症性
sponse in perianal Crohn’s disease[J]. J Crohns Colitis， 肠病治疗药物监测专家共识意见[J]. 中华消化杂志，
2017，11（5）：549-555. 2018，38（11）：721-727.
[ 7 ] DREESEN E，D’HAENS G，BAERT F，et al. DOP047 Inf‐ Committee of Inflammatory Bowel Disease，Chinese Socie-
liximab exposure predicts superior endoscopic outcomes ty of Gastroenterology. Chinese consensus on therapeutic
in patients with active Crohn’s disease：pharmacokinetic- drug monitoring in inflammatory bowel disease[J]. Chin J
pharmacodynamic analysis of TAILORIX[J]. J Crohns Dig，2018，38（11）：721-727.
Colitis，2018，12（supplement_1）：S063-S064. [18] 林荣芳，郑玮玮，林玮玮，等. 克罗恩病患者英夫利西单
[ 8 ] SPARROW M P，PAPAMICHAEL K，WARD M G，et al. 抗谷浓度分布及影响因素分析[J]. 中国医院药学杂志，
Therapeutic drug monitoring of biologics during induction 2021，41（10）：1035-1039.
to prevent primary non-response[J]. J Crohns Colitis， LIN R F，ZHENG W W，LIN W W，et al. Distribution of
2020，14（4）：542-556. infliximab trough concentration and its influencing factors
[ 9 ] SYVERSEN S W，GOLL G L，JØRGENSEN K K，et al. in patients with Crohn’s disease[J]. Chin J Hosp Pharm，
Effect of therapeutic drug monitoring vs standard therapy 2021，41（10）：1035-1039.
during infliximab induction on disease remission in pa‐ [19] DREESEN E，BERENDS S，LAHARIE D，et al. Model‐
tients with chronic immune-mediated inflammatory di- ling of the relationship between infliximab exposure，fae‐
seases：a randomized clinical trial[J]. JAMA，2021，325 cal calprotectin and endoscopic remission in patients with
（17）：1744-1754. Crohn’s disease[J]. Br J Clin Pharmacol，2021，87（1）：
[10] CHEIFETZ A S，ABREU M T，AFIF W，et al. A compre‐ 106-118.
hensive literature review and expert consensus statement [20] KHANNA R，LEVESQUE B G，SANDBORN W J，et al.
on therapeutic drug monitoring of biologics in inflamma‐ Therapeutic drug monitoring of TNF antagonists in in‐
tory bowel disease[J]. Am J Gastroenterol，2021，116 flammatory bowel disease[J]. Gastroenterol Hepatol，
（10）：2014-2025. 2014，10（8）：478-489.
[11] CORNILLIE F，HANAUER S B，DIAMOND R H，et al. [21] BUURMAN D J，MAURER J M，KEIZER R J，et al.
Postinduction serum infliximab trough level and decrease Population pharmacokinetics of infliximab in patients
of C-reactive protein level are associated with durable sus‐ with inflammatory bowel disease：potential implications
tained response to infliximab：a retrospective analysis of for dosing in clinical practice[J]. Aliment Pharmacol Ther，
the ACCENT Ⅰ trial[J]. Gut，2014，63（11）：1721-1727. 2015，42（5）：529-539.
[12] PAPAMICHAEL K，RAKOWSKY S，RIVERA C，et al. [22] KANTASIRIPITAK W，VERSTOCKT B，ALSOUD D，et
Association between serum infliximab trough concentra‐ al. The effect of aging on infliximab exposure and re‐
tions during maintenance therapy and biochemical，endo‐ sponse in patients with inflammatory bowel diseases[J].
scopic，and histologic remission in Crohn’s disease[J]. In‐ Br J Clin Pharmacol，2021，87（10）：3776-3789.
flamm Bowel Dis，2018，24（10）：2266-2271. [23] CHANG H P，SHAKHNOVICH V，FRYMOYER A，et al.
[13] YARUR A J，KANAGALA V，STEIN D J，et al. Higher A population physiologically-based pharmacokinetic
infliximab trough levels are associated with perianal fis‐ model to characterize antibody disposition in pediatrics
tula healing in patients with Crohn’s disease[J]. Aliment and evaluation of the model using infliximab[J]. Br J Clin
Pharmacol Ther，2017，45（7）：933-940. Pharmacol，2022，88（1）：290-302.
[14] VANDE CASTEELE N，FERRANTE M，VAN ASSCHE [24] FASANMADE A A，ADEDOKUN O J，BLANK M，et al.
G，et al. Trough concentrations of infliximab guide dosing Pharmacokinetic properties of infliximab in children and
for patients with inflammatory bowel disease[J]. Gastroen‐ adults with Crohn’s disease：a retrospective analysis of
terology，2015，148（7）：1320-1329.e3. data from 2 phase Ⅲ clinical trials[J]. Clin Ther，2011，33
[15] FEUERSTEIN J D，NGUYEN G C，KUPFER S S，et al. （7）：946-964.
American Gastroenterological Association institute guide‐ [25] MATSUOKA K，HAMADA S，SHIMIZU M，et al. Fac‐
line on therapeutic drug monitoring in inflammatory tors contributing to the systemic clearance of infliximab

中国药房 2023年第34卷第24期 China Pharmacy 2023 Vol. 34 No. 24 · 3071 ·